Epidemiology — MCQs

Epidemiology Indian Medical PG Practice Questions and MCQs

Question 1221: Which of the following diseases does not require mandatory surveillance?

A. Polio
B. Viral encephalitis (Correct Answer)
C. Malaria
D. Relapsing fever

Explanation: ### Explanation The concept of **Mandatory Surveillance** (or Notifiable Diseases) refers to diseases that, by law, must be reported to government or health authorities. This allows for early detection of outbreaks and monitoring of global health security. **Why Viral Encephalitis is the correct answer:** Under the **International Health Regulations (IHR)** and national surveillance guidelines, specific diseases are prioritized based on their epidemic potential or eradication status. While "Japanese Encephalitis" is a notifiable disease in many endemic regions (like India), the broad category of **"Viral Encephalitis"** is generally not listed as a globally mandatory reportable condition in the same way specific high-threat pathogens are. It is often monitored through sentinel surveillance rather than universal mandatory notification. **Analysis of Incorrect Options:** * **Polio (A):** As a disease targeted for global eradication, even a single case of Poliomyelitis is considered a public health emergency of international concern (PHEIC) and must be reported immediately. * **Malaria (C):** It is a major public health threat with high morbidity. In India, under the National Framework for Malaria Elimination, notification of all malaria cases (by both public and private sectors) is mandatory to ensure complete mapping and treatment. * **Relapsing Fever (D):** Historically, Louse-borne relapsing fever is one of the specific diseases mentioned under older International Sanitary Regulations and remains a reportable disease in many jurisdictions due to its potential for rapid spread in crowded conditions. **High-Yield Clinical Pearls for NEET-PG:** * **IHR (2005):** Requires notification of all cases of **Smallpox, Polio (wild type), Human Influenza (new subtype), and SARS.** * **Integrated Disease Surveillance Programme (IDSP):** In India, diseases are classified into "P" (Presumptive), "S" (Suspected), and "L" (Laboratory confirmed) formats. * **Immediate Notification:** Diseases like Measles, Cholera, and Plague require immediate reporting to prevent explosive outbreaks.

Question 1222: IFA supplementation is an example of which level of disease prevention?

A. Primordial prevention
B. Specific protection (Correct Answer)
C. Secondary prevention
D. Tertiary prevention

Explanation: **Explanation:** The correct answer is **Specific Protection**, which is a sub-component of **Primary Prevention**. **Why Specific Protection is correct:** Primary prevention aims to prevent the onset of disease by intervening before the disease process begins. It is divided into two categories: Health Promotion and Specific Protection. **Specific Protection** involves measures directed toward a particular disease or group of diseases. Since Iron and Folic Acid (IFA) supplementation is a targeted nutritional intervention designed specifically to prevent nutritional deficiency anemia, it falls under this category. Other examples include immunizations and the use of condoms to prevent STIs. **Why the other options are incorrect:** * **Primordial Prevention:** This involves preventing the emergence of risk factors (e.g., discouraging children from starting smoking). Since IFA is given when the risk factor (nutritional deficiency/increased demand) is already present or anticipated, it is not primordial. * **Secondary Prevention:** This focuses on early diagnosis and prompt treatment (e.g., screening tests like Pap smears). IFA supplementation is prophylactic, not a diagnostic tool for existing disease. * **Tertiary Prevention:** This aims to reduce disability and facilitate rehabilitation in late stages of disease. **High-Yield Clinical Pearls for NEET-PG:** * **Anemia Mukt Bharat (AMB):** Uses a "6x6x6" strategy. Note the prophylactic IFA dosage for pregnant women: **100 mg elemental Iron and 500 mcg Folic Acid** daily for 180 days, starting from the second trimester. * **Vitamin A Prophylaxis:** Also an example of Specific Protection. * **Key Distinction:** If a question asks for the "Level of Prevention" and "Primary Prevention" is an option alongside "Specific Protection," choose **Primary Prevention** unless the question specifically asks for the sub-type.

Question 1223: Good clinical practices (GCP) are not a part of which of the following trial phases?

A. Phase I Clinical Trials
B. Phase II Clinical Trials
C. Phase IV clinical trials
D. Pre-clinical trials (Correct Answer)

Explanation: **Explanation:** **Good Clinical Practice (GCP)** is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve the participation of **human subjects**. 1. **Why Pre-clinical trials is the correct answer:** Pre-clinical trials are conducted in **laboratories and on animal models** (in vitro and in vivo) to assess safety and biological activity before a drug is tested in humans. Because GCP specifically governs research involving human participants, it does not apply here. Instead, pre-clinical studies must adhere to **Good Laboratory Practices (GLP)** and guidelines for animal ethics. 2. **Why the other options are incorrect:** * **Phase I (Human Pharmacology):** Focuses on safety and dosage in a small group of healthy volunteers. Since humans are involved, GCP is mandatory. * **Phase II (Therapeutic Exploratory):** Focuses on efficacy and side effects in a small group of patients. GCP compliance ensures patient safety and data integrity. * **Phase IV (Post-Marketing Surveillance):** Occurs after the drug is marketed to detect rare adverse effects. Even in this observational phase, GCP standards must be maintained to protect patient rights. **High-Yield Clinical Pearls for NEET-PG:** * **GCP Objective:** To ensure the rights, safety, and well-being of trial subjects are protected and that clinical trial data are credible. * **The Declaration of Helsinki:** This is the historical cornerstone document that forms the basis of GCP. * **Phase 0 Trials:** Also known as "Microdosing" studies; these also require GCP as they involve human subjects. * **GLP vs. GCP:** Remember: **GLP** = Laboratory/Animals; **GCP** = Clinical/Humans.

Question 1224: In a demographic study of a population, a country with a low birth rate and a low death rate is in which phase?

A. 1st phase
B. 2nd phase
C. 3rd phase
D. 4th phase (Correct Answer)

Explanation: ### Explanation The question refers to the **Demographic Transition Model**, which describes the historical shift of a population from high birth and death rates to low birth and death rates as a country develops. **Why Option D is Correct:** The **4th Phase (Low Stationary Stage)** is characterized by both **low birth rates and low death rates**. In this stage, the population becomes stable (zero population growth). Modern developed nations like Japan, the UK, and many European countries are currently in this phase. The birth rate has declined to match the already low death rate, leading to an aging population. **Why Other Options are Incorrect:** * **Option A (1st Phase - High Stationary):** Characterized by both **high birth and high death rates**. The population remains stable but at a low level. This was seen globally before the industrial revolution. * **Option B (2nd Phase - Early Expanding):** The death rate begins to decline due to better healthcare and sanitation, but the **birth rate remains high**. This leads to the beginning of a "population explosion." * **Option C (3rd Phase - Late Expanding):** The death rate continues to decline further, and the **birth rate also begins to fall**, but the birth rate still exceeds the death rate, leading to continued population growth. **India** is currently considered to be in late Phase 3. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 5 (Declining Stage):** Some models include a 5th stage where the birth rate falls *below* the death rate, leading to a population decrease (e.g., Germany, Hungary). * **India’s Status:** India is transitioning from Phase 3 to Phase 4. * **Key Driver:** The transition from Phase 2 to Phase 3 is primarily driven by improvements in female literacy and access to contraception. * **The "Gap":** The widening gap between birth and death rates in Phase 2 is what causes the most rapid population growth.

Question 1225: What is the incubation period for Hepatitis A?

A. 2-6 weeks (Correct Answer)
B. 12 weeks
C. 8 weeks
D. 10 weeks

Explanation: **Explanation:** **Hepatitis A Virus (HAV)** is a small, non-enveloped RNA virus transmitted primarily via the **fecal-oral route**. The incubation period refers to the interval between exposure to the pathogen and the appearance of the first clinical sign or symptom. 1. **Why Option A is correct:** The standard incubation period for Hepatitis A is **10 to 50 days**, with an average of approximately **28 days (4 weeks)**. Therefore, the range of **2–6 weeks** accurately captures the typical clinical window for symptom onset following ingestion of contaminated food or water. 2. **Why other options are incorrect:** * **Options B, C, and D (8, 10, and 12 weeks):** These durations are too long for Hepatitis A. An incubation period of 8–12 weeks is more characteristic of **Hepatitis B** (range: 45–180 days; average 60–90 days) or **Hepatitis C** (range: 2 weeks to 6 months; average 6–9 weeks). **High-Yield Clinical Pearls for NEET-PG:** * **Maximum Infectivity:** A patient is most infectious during the **late incubation period** (2 weeks before the onset of jaundice), when fecal shedding of the virus is at its peak. * **Diagnosis:** The presence of **IgM anti-HAV** is the gold standard for diagnosing acute infection. IgG anti-HAV indicates past exposure or immunity. * **Epidemiology:** In India, HAV is the most common cause of acute viral hepatitis in children. It does **not** cause chronic carrier states or cirrhosis. * **Prevention:** Control is achieved through improved sanitation and the **Hepatitis A vaccine** (given in two doses, 6 months apart). Post-exposure prophylaxis with the vaccine or immunoglobulin is effective if administered within **2 weeks** of exposure.

Question 1226: What was the estimated life expectancy as per the 2015 estimate?

A. 68.3 years (Correct Answer)
B. 62.3 years
C. 58.1 years
D. 55 years

Explanation: **Explanation:** Life expectancy at birth is a key indicator of the health status of a population and a core component of the Physical Quality of Life Index (PQLI) and Human Development Index (HDI). **Why Option A is Correct:** According to the **Sample Registration System (SRS) data** and the World Health Statistics, the estimated life expectancy at birth for India in **2015** was approximately **68.3 years** (66.9 years for males and 70.0 years for females). This reflects a steady improvement in public health interventions, maternal and child health care, and the control of infectious diseases over the decades. **Analysis of Incorrect Options:** * **Option B (62.3 years):** This figure represents the life expectancy in India during the late 1990s and early 2000s (approx. 1996–2001). * **Option C (58.1 years):** This was the approximate life expectancy in the mid-1980s. * **Option D (55 years):** This figure corresponds to the life expectancy in India during the early 1980s. **High-Yield Pearls for NEET-PG:** * **Current Trend:** As per the latest SRS data (2016–2020), the life expectancy in India has further increased to **69.7 years**. * **Gender Gap:** In India, life expectancy for **females** is consistently higher than for males, a trend seen globally due to biological and behavioral factors. * **Definition:** Life expectancy at birth is the average number of years a newborn is expected to live if current mortality rates continue. * **Best Indicator:** While Life Expectancy at birth is a general health indicator, **Infant Mortality Rate (IMR)** is considered the most sensitive indicator of a community's health status and socioeconomic development.

Question 1227: Which of the following are arboviral diseases?

A. Japanese encephalitis
B. Dengue
C. Yellow fever
D. All of the above (Correct Answer)

Explanation: **Explanation:** The term **Arbovirus** is a descriptive name for a group of viruses that are **Ar**thropod-**bo**rne. These viruses are transmitted to humans through the bite of infected arthropods, primarily mosquitoes, ticks, and sandflies. **Why the correct answer is "All of the above":** All three diseases listed are classic examples of arboviral infections caused by viruses belonging to the *Flaviviridae* family: * **Japanese Encephalitis (JE):** Transmitted by the *Culex tritaeniorhynchus* mosquito. It is the leading cause of viral encephalitis in Asia. * **Dengue:** Transmitted primarily by *Aedes aegypti* (and *Aedes albopictus*). It is the most common mosquito-borne viral disease globally. * **Yellow Fever:** Also transmitted by *Aedes aegypti*. While not endemic in India, it remains a significant global health concern and a frequent topic in international health regulations. **High-Yield Clinical Pearls for NEET-PG:** 1. **Vector Identification:** * *Aedes:* Dengue, Chikungunya, Yellow Fever, Zika. * *Culex:* Japanese Encephalitis, West Nile Virus, Bancroftian Filariasis. * *Anopheles:* Malaria (Protozoal, not viral). 2. **Reservoirs:** For JE, the amplifying hosts are **pigs** and water birds (Ardeid birds). 3. **Vaccination:** Yellow fever requires a mandatory international certificate of vaccination (17D strain) for travelers coming from endemic zones to India. 4. **Extrinsic Incubation Period:** This is the time taken for the virus to multiply within the mosquito before it becomes infective to another human.

Question 1228: What is the amplifier host in Japanese Encephalitis?

A. Man
B. Culex mosquito
C. Pig (Correct Answer)
D. Horse

Explanation: **Explanation:** Japanese Encephalitis (JE) is a zoonotic viral infection caused by a Group B Arbovirus (Flavivirus). Understanding the transmission cycle is crucial for NEET-PG, as the roles of different hosts are frequently tested. **Why Pig is the Correct Answer:** The **Pig** is the **amplifier host**. In JE, the virus undergoes rapid multiplication in the pig's body without causing clinical disease. This results in a high-titer viremia (prolonged and intense) that is sufficient to infect the *Culex* mosquito during a blood meal. Pigs act as a "link" between the natural cycle and human habitats. **Analysis of Incorrect Options:** * **Man (Dead-end Host):** Humans are "dead-end" hosts because the level and duration of viremia in humans are too low to infect a biting mosquito. Humans do not contribute to the transmission cycle. * **Culex mosquito (Vector):** *Culex tritaeniorhynchus* is the primary vector. It is the vehicle of transmission, not the amplifier host. * **Horse (Dead-end Host):** Like humans, horses develop clinical disease but do not maintain a high enough viremia to infect mosquitoes. **High-Yield Clinical Pearls for NEET-PG:** * **Natural Reservoir/Maintenance Host:** Ardeid birds (Cattle egrets, Herons). They maintain the virus in nature. * **Primary Vector:** *Culex tritaeniorhynchus* (breeds in stagnant water like rice fields). * **Biting Habit:** Primarily **exophilic** (outdoors) and **zoophilic** (prefers animals), biting mostly at dusk. * **Sentinel Animals:** Pigs are used as sentinels to monitor the arrival of the virus in a community. * **Vaccination:** The most common vaccine used in the National Immunization Schedule (NIS) in India is the **SA-14-14-2** (Live attenuated, Chinese origin).

Question 1229: Which of the following diseases does not typically have carriers?

A. Rabies (Correct Answer)
B. Typhoid fever
C. Polio
D. Malaria

Explanation: **Explanation:** The correct answer is **Rabies (Option A)**. In epidemiology, a **carrier** is an infected person or animal that harbors a specific infectious agent without having clinical disease and serves as a potential source of infection for others. **Why Rabies is the correct answer:** Rabies is a fatal viral encephalitis where the virus is transmitted via the saliva of infected animals. The disease follows an "all-or-none" phenomenon: once the virus reaches the central nervous system and symptoms appear, it is invariably fatal (with extremely rare exceptions). There is **no chronic carrier state** in humans or the primary reservoirs (like dogs); the animal either remains healthy or develops the disease and dies within a short period (usually 10 days). **Analysis of Incorrect Options:** * **Typhoid Fever:** A classic example of the carrier state. About 2-5% of cases become chronic carriers (e.g., "Typhoid Mary"), harboring *Salmonella typhi* in the gallbladder. * **Polio:** Poliovirus frequently results in **inapparent (asymptomatic) infections**, which act as temporary carriers, shedding the virus in feces and spreading it to others. * **Malaria:** Humans act as reservoirs for *Plasmodium* parasites. Asymptomatic individuals can harbor gametocytes in their blood for extended periods, allowing mosquitoes to pick up the infection. **High-Yield NEET-PG Pearls:** 1. **Diseases with NO Carriers:** Rabies, Measles, Smallpox, and Pertussis. 2. **Pseudocarrier:** A term sometimes used for the "incubatory carrier" stage, but in the context of Rabies, the rapid progression to death precludes a true carrier state. 3. **Epidemiological Importance:** Diseases without a carrier state are generally easier to eradicate (e.g., Smallpox) because there is no "hidden" reservoir in the population.

Question 1230: Which of the following methods is ideal to ensure similarity between experimental and control groups?

A. Randomization
B. Stratified randomization (Correct Answer)
C. Matching
D. Cross-over study

Explanation: **Explanation:** In experimental studies, the goal is to ensure that the study and control groups are as identical as possible, except for the intervention being tested. **1. Why Stratified Randomization is Correct:** While simple randomization ensures that every participant has an equal chance of being assigned to a group, it may fail to balance specific prognostic factors (like age, sex, or disease severity) in smaller samples. **Stratified Randomization** is the ideal method because it first categorizes participants into "strata" based on these important variables and then performs randomization within each stratum. This guarantees that both groups are perfectly balanced for known confounding factors, ensuring maximum similarity. **2. Analysis of Incorrect Options:** * **Randomization (Simple):** This is the "heart" of a clinical trial and eliminates selection bias. However, by chance, it may result in an imbalance of key variables between groups, especially in small studies. * **Matching:** This is primarily used in **Case-Control studies** to eliminate confounding. It is difficult, time-consuming, and can lead to "over-matching." It does not account for unknown confounders, whereas randomization does. * **Cross-over Study:** This is a study design where the same subject serves as their own control (receiving both treatment and placebo at different times). While it ensures perfect similarity, it is a **design type**, not a method used to *create* groups in a standard parallel trial. **High-Yield Pearls for NEET-PG:** * **Randomization** is the best method to control for **unknown confounders**. * **Blinding** is used to eliminate **ascertainment (observer) bias**. * **Stratification** is used to control for **known confounders** at the design stage. * The "Unit of Randomization" in a standard Clinical Trial is the **Individual**, while in a Community Trial, it is the **Group/Community**.

Practice by Chapter

Principles of Epidemiology

Practice Questions

Measures of Disease Frequency

Practice Questions

Epidemiological Study Designs

Practice Questions

Descriptive Epidemiology

Practice Questions

Analytical Epidemiology

Practice Questions

Experimental Epidemiology

Practice Questions

Screening for Disease

Practice Questions

Surveillance Systems

Practice Questions

Investigation of an Epidemic

Practice Questions

Association and Causation

Practice Questions

Modern Epidemiological Methods

Practice Questions

Critical Appraisal of Epidemiological Studies

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free